Hebrew University of Jerusalem

Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment

Retrieved on: 
星期二, 五月 7, 2024
Hebrew University of Jerusalem, Selective serotonin reuptake inhibitor, Weight gain, Hope, Post-traumatic stress disorder, Nausea, PTSD, Al-Quds, Insomnia, Serotonin–norepinephrine reuptake inhibitor, Therapy, Intellectual property, Anxiety, Pharmaceutical industry

This agreement provides Clearmind with exclusive global rights to further develop, manufacture, and commercialize innovative compounds invented by Professors Rami Yaka, Ahmed Masaewa and Avi Priel from the Hebrew University.

Key Points: 
  • This agreement provides Clearmind with exclusive global rights to further develop, manufacture, and commercialize innovative compounds invented by Professors Rami Yaka, Ahmed Masaewa and Avi Priel from the Hebrew University.
  • These novel compounds are targeted at treating post-traumatic stress disorder (PTSD) and other mental health conditions.
  • The global market for PTSD treatment, valued at $16.8 billion in 2023, is expected to reach $27.37 billion by 2033, according to Future Market Insights.
  • Under the terms of the agreement, Clearmind receives exclusive rights to develop, manufacture, and commercialize novel compounds for treating PTSD and other mental health disorders.

Similarweb Appoints Rami Myerson to Lead Investor Relations

Retrieved on: 
星期一, 五月 6, 2024
Software, Mobile, Wireless, Internet, Professional Services, Search Engine Optimization, Search Engine Marketing, Data Management, Technology, Data Analytics, Marketing, Advertising, Communications, Hebrew University of Jerusalem, Elbit Systems, Al-Quds, Head, CFA, Defense

Similarweb Ltd. (NYSE: SMWB), a leading digital data and web analytics company, announced the appointment of Rami Myerson as Vice President, Investor Relations, effective immediately.

Key Points: 
  • Similarweb Ltd. (NYSE: SMWB), a leading digital data and web analytics company, announced the appointment of Rami Myerson as Vice President, Investor Relations, effective immediately.
  • Myerson joins Similarweb from Elbit Systems, a $9 billion defense technology company, where since 2019 he had served as Head of Investor Relations.
  • Before that, he spent 12 years as a sell-side equity research analyst in London and Tel-Aviv, covering Aerospace and Defense and Israeli companies.
  • Myerson holds a BA in Economics and Middle Eastern Studies from the Hebrew University and is a CFA Charterholder.

Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders

Retrieved on: 
星期三, 四月 17, 2024
Hebrew University of Jerusalem, IP, Safety, Partnership, Research, DSM-IV codes, Therapy, Al-Quds, Patient, Pharmaceutical industry

This partnership marks a significant step in harnessing generation 3.0 psychedelic compounds, methods of their preparation, and uses thereof in the treatment of addiction and mental disorders.

Key Points: 
  • This partnership marks a significant step in harnessing generation 3.0 psychedelic compounds, methods of their preparation, and uses thereof in the treatment of addiction and mental disorders.
  • Dr. Adi Zuloff-Shani, CEO of Clearmind, commented, "We are witnessing a renaissance within psychedelic medicine, including broad acknowledgment of these therapies and their potential by the medical community.
  • In particular, there has been a rise in demand for a new class of innovative compounds with enhanced psychedelic properties.
  • Under the terms of the agreement, Clearmind receives exclusive worldwide rights to develop, research, manufacture, market, and commercialize products derived from a patent-pending synthesis of psychedelic compounds, enriching the company’s innovative portfolio in addiction and mental health treatments.

Renowned Industry Expert Peter Kyobe Waiswa Joins XRP Healthcare to transform Private Healthcare in Uganda

Retrieved on: 
星期二, 四月 16, 2024
XRP, College of Health Sciences, Public health, School, Organization, Health policy, Hebrew University of Jerusalem, UNICEF, Karolinska Institute, Adolescence, The, WHO, Science, Outline of health sciences, Health, Mbarara University, Makerere University, Business development, Research, Master, Bill, Working group, Non-governmental organization, Adolescent health, Mother, Knowledge

DUBAI, UAE, April 16, 2024 /PRNewswire/ -- XRP Healthcare, a UAE-based M&A healthcare investment and management firm, proudly announces the appointment of Peter Kyobe Waiswa as a Healthcare Industry Expert.

Key Points: 
  • DUBAI, UAE, April 16, 2024 /PRNewswire/ -- XRP Healthcare, a UAE-based M&A healthcare investment and management firm, proudly announces the appointment of Peter Kyobe Waiswa as a Healthcare Industry Expert.
  • "I am thrilled to join XRP Healthcare and contribute to the transformation of Uganda's private healthcare sector," said Peter Kyobe Waiswa.
  • Whitney Lynn, XRP Healthcare Chairman commented, "We are humbled to have Peter Kyobe Waiswa join our team at XRP Healthcare.
  • Kain Roomes, founder and CEO of XRP Healthcare said, "We are elated to welcome Peter Kyobe Waiswa into the XRP Healthcare family.

Renowned Industry Expert Peter Kyobe Waiswa Joins XRP Healthcare to transform Private Healthcare in Uganda

Retrieved on: 
星期二, 四月 16, 2024
XRP, College of Health Sciences, Public health, School, Organization, Health policy, Hebrew University of Jerusalem, UNICEF, Karolinska Institute, Adolescence, The, WHO, Science, Outline of health sciences, Health, Mbarara University, Makerere University, Business development, Research, Master, Bill, Working group, Non-governmental organization, Adolescent health, Mother, Knowledge

DUBAI, UAE, April 16, 2024 /PRNewswire/ -- XRP Healthcare, a UAE-based M&A healthcare investment and management firm, proudly announces the appointment of Peter Kyobe Waiswa as a Healthcare Industry Expert.

Key Points: 
  • DUBAI, UAE, April 16, 2024 /PRNewswire/ -- XRP Healthcare, a UAE-based M&A healthcare investment and management firm, proudly announces the appointment of Peter Kyobe Waiswa as a Healthcare Industry Expert.
  • "I am thrilled to join XRP Healthcare and contribute to the transformation of Uganda's private healthcare sector," said Peter Kyobe Waiswa.
  • Whitney Lynn, XRP Healthcare Chairman commented, "We are humbled to have Peter Kyobe Waiswa join our team at XRP Healthcare.
  • Kain Roomes, founder and CEO of XRP Healthcare said, "We are elated to welcome Peter Kyobe Waiswa into the XRP Healthcare family.

Inspira™ and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth that Causes Bloodstream Infections

Retrieved on: 
星期三, 四月 10, 2024
Hebrew University of Jerusalem, Bacteria, Physiology, Research, Environment, ART, Al-Quds, Patient, OXY, Allergy, Intensive care medicine, Pharmaceutical industry

Once developed, Inspira plans to integrate the bio-electronic novel physical stimulation technology, into the INSPIRA™ ART patient treatment.

Key Points: 
  • Once developed, Inspira plans to integrate the bio-electronic novel physical stimulation technology, into the INSPIRA™ ART patient treatment.
  • The results of the in vitro study showed a 75% reduction in bacterial growth 4 hours after the application of the treatment and a 100% reduction within 24 hours.
  • The in vitro study was carried out at the Hebrew University of Jerusalem and involved testing bioelectric patches in an in vitro environment.
  • As part of the in vitro study, bacteria were cultured and spread on agar in petri dishes.

AVI WIGDERSON RECEIVES ACM A.M. TURING AWARD FOR GROUNDBREAKING INSIGHTS ON RANDOMNESS

Retrieved on: 
星期三, 四月 10, 2024
EXPTIME, School, American Academy, Hebrew University of Jerusalem, University, IMU Abacus Medal, BPP, Nature, Computer science, Science, ACM, Hope, Computing, National academy, ACM Fellow, Princeton University, Heart, Machine learning, Abel Prize, Nobel Prize, Computer, Computational biology, Doctor of Philosophy, Research, Nevanlinna, Russell Impagliazzo, Algorithm, Senior, Al-Quds, Hardness, Prize, Turing Award, IBM, Information technology

NEW YORK, April 10, 2024 /PRNewswire/ -- ACM, the Association for Computing Machinery, today named Avi Wigderson as recipient of the 2023 ACM A.M. Turing Award for foundational contributions to the theory of computation, including reshaping our understanding of the role of randomness in computation, and for his decades of intellectual leadership in theoretical computer science.

Key Points: 
  • The ACM A.M. Turing Award, often referred to as the "Nobel Prize of Computing," carries a $1 million prize.
  • The ACM A.M. Turing Award, often referred to as the "Nobel Prize of Computing," carries a $1 million prize with financial support provided by Google, Inc.
  • The award is named for Alan M. Turing, the British mathematician who articulated the mathematical foundations of computing.
  • We congratulate Avi Wigderson on receiving the ACM A.M. Turing Award—computing's highest honor."

Mitesco Announces Advisory Board Appointments

Retrieved on: 
星期二, 三月 19, 2024
Department of Defence, CPG, Evolution Fresh, Emory University, Thein, Coca-Cola, Information, Park University, PepsiCo, SDVOSB, Advisory board, Public policy, Hebrew University of Jerusalem, University, OTC, Liberty University, Starbucks, Engineering, MIS, Odwalla, CIPP, Corporate title, Advisory, Marketing, Service-Disabled Veteran-Owned Small Business, MITI, Le Cordon Bleu, Arms industry

VERO BEACH, FL, March 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Mitesco, Inc. (OTC:MITI, “the Company”, www.mitescoinc.com ) today announced that it has appointed three (3) professionals to its recently formed “Advisory Board”.

Key Points: 
  • VERO BEACH, FL, March 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Mitesco, Inc. (OTC:MITI, “the Company”, www.mitescoinc.com ) today announced that it has appointed three (3) professionals to its recently formed “Advisory Board”.
  • The Board will be comprised of individuals with specific subject matter expertise who may assist the Company in finding and evaluating qualified companies.
  • The Advisory Board is a non-executive board, and its participants shall not be subject to any of the regulations under Section 16 of the Securities Act.
  • The initial appointments to the Advisory Board are as follows:
    With a career in data security, Ms. Kristen Plybon is a cybersecurity professional with a strong background in data privacy with CIPP/US and CIPP/E certifications.

Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin

Retrieved on: 
星期一, 三月 18, 2024
Survival, JCO, Caregiver, Therapy, Palliative care, Patient, Ethics, Journal, Mouse, Research, Hebrew University of Jerusalem, Anxiety, MD, Nature, Quality of life, Adjustment disorder, World Health Organization, Adjustment, ASCO, Molecular Psychiatry, WHO, Paper, FDA, PBM

NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq:PBM) ("Psyence Biomed" or the "Company") today issued a statement welcoming the results of a recent study finding evidence that nature-derived psilocybin may be demonstrably more therapeutic than synthetic psilocybin.

Key Points: 
  • The study presents evidence that nature (mushroom)-derived psilocybin delivers a “more potent and prolonged effect” on “neuroplasticity” than its synthetic analog.
  • “Neuroplasticity” is increasingly recognized as the gold standard by which the therapeutic efficacy of psychedelic pharmaceutical medicines can be measured.
  • The Psyence Biomed study will examine the use of nature-derived psilocybin as a treatment for Adjustment Disorder due to a recent cancer diagnosis in the Palliative Care context.
  • Neither Psyence Biomedical nor any of its investors or affiliates funded or in any way sponsored the Hebrew University study.

Edgewood Oncology Emerges From Stealth with $20 Million in Series A Financing to Advance BTX-A51 in Patients with Hematologic Malignancies and Genetically-Defined Solid Tumors

Retrieved on: 
星期一, 三月 25, 2024
Science, Biotechnology, Research, Oncology, General Health, Health, Genetics, Clinical Trials, Toxicity, CDK7, Apoptosis, Hebrew University of Jerusalem, CRH, CRi, AML, Patient, Immunology, Acute myeloid leukemia, Cancer, Medicine, Alta Partners, Therapy, Drug development, Breast cancer, Safety, Azacitidine, Pharmacokinetics, CDK9, Bone marrow, Pharmaceutical industry

Edgewood acquired the rights to BTX-A51 from Yissum, the technology transfer company of The Hebrew University of Jerusalem, in 2023 and will use the Series A funding to advance efficacy studies in AML and breast cancer.

Key Points: 
  • Edgewood acquired the rights to BTX-A51 from Yissum, the technology transfer company of The Hebrew University of Jerusalem, in 2023 and will use the Series A funding to advance efficacy studies in AML and breast cancer.
  • “We formed Edgewood Oncology because of the synergistic mechanism of action and promising safety and anti-tumor data that was observed with BTX-A51 in Phase 1 in AML and solid tumor patients.
  • In a Phase 1 study in heavily pre-treated R/R AML patients, monotherapy BTX-A51 demonstrated a favorable safety profile and encouraging antileukemic activity.
  • As a next step, Edgewood initiated a study of BTX-A51 in combination with azacitidine in R/R AML patients in December 2023.